Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

@article{Athyros2006EffectOM,
  title={Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study},
  author={V. Athyros and D. Mikhailidis and T. P. Didangelos and O. Giouleme and E. Liberopoulos and A. Karagiannis and A. Kakafika and K. Tziomalos and A. Burroughs and M. Elisaf},
  journal={Current Medical Research and Opinion},
  year={2006},
  volume={22},
  pages={873 - 883}
}
  • V. Athyros, D. Mikhailidis, +7 authors M. Elisaf
  • Published 2006
  • Medicine
  • Current Medical Research and Opinion
  • ABSTRACT Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS). There is no established treatment for NAFLD. Aim: To evaluate a multifactorial intervention in the treatment of NAFLD. Methods: A prospective, open-label, randomised study in non-diabetic patients (n = 186) with MetS (follow-up: 54 weeks). All patients had both biochemical and ultrasonographic evidence of NAFLD at baseline. Other causes of liver disease were excluded… CONTINUE READING
    215 Citations
    Statins for non‐alcoholic fatty liver disease: a new indication?
    • 27
    Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease
    • 3
    The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
    • PDF
    Therapy of nonalcoholic fatty liver disease: current status.
    • 75
    • PDF
    Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies
    • 56

    References

    SHOWING 1-10 OF 59 REFERENCES
    Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    • 62
    Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.
    • 163
    Association of nonalcoholic fatty liver disease with insulin resistance.
    • 1,368
    • PDF